

1 April 2026

Bioxyne Signs Manufacturing Agreement with Global Cannabis Leader, Aurora Cannabis

Australian Bioxyne Limited (ASX: BXN) (“**Bioxyne**” or “**the Company**”), through its wholly owned subsidiary **Breathe Life Sciences (BLS)**, is pleased to announce that it has entered into a manufacturing agreement with **Aurora Cannabis Inc. (NASDAQ / TSX: ACB)** (“**Aurora**”), the Canadian-based leading global medical cannabis company.

Key Highlights

- Manufacturing agreement signed with Aurora, one of the world’s largest medical cannabis producers
- Initial agreement covers supply of GMP-certified medicinal cannabis oils into the Australian market, with initial deliveries already completed
- Agreement expanding to include GMP-manufactured cannabis vapes for supply into Australia, the United Kingdom and Germany
- This partnership underscores Bioxyne’s growing creditability as a global player in pharmaceutical-grade cannabis manufacturing and its ability to deliver high-quality, scalable solutions

Overview

Under the agreement, BLS will manufacture pharmaceutical-grade medicinal cannabis products for supply into key international markets. This collaboration highlights Bioxyne's evolution from a leading Australian manufacturer to a globally recognised brand, capable of partnering with top-tier industry leaders like Aurora, to meet the demands of highly-regulated, high-stakes environments.

The agreement marks a significant validation of Bioxyne's GMP-certified expertise in producing precision-dosed cannabis formats, positioning the Company as a trusted supplier on the world stage.

Chief Executive Officer Sam Watson commented:

“This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities. We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth.”



Alex Miller, Executive Vice President, Operations & Supply Chain for Aurora commented:

“As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”

The companies have agreed to expand the scope of the manufacturing agreement and the onboarding process for the supply of additional product lines has commenced.

This expansion includes a large quantity of vapes, which will be produced and distributed into the Australian, UK and German markets.

Discussions are also progressing regarding the production of further products for supply into the for the Australian, UK and German markets, further expanding BLS's manufacturing capabilities and market presence.

Key Commercial Terms

Initial Products: Medicinal cannabis oils

Expansion: GMP-manufactured cannabis vapes, with additional lines to be confirmed

Term: initial 12-month rolling term with automatic renewal and terminable only on 6 months' notice

Approved by the Board of Bioxyne Limited for release to the ASX.

For further information, please contact:

Bioxyne Limited
Sam Watson
Chief Executive Officer
info@bioxyne.com

NWR Communications
Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

For personal use only



About Bioxyne Ltd.

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - United Kingdom: drwatsoncbd.com
 - Japan: nolcbn.com
 - UK / EU: breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com



About Aurora

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora[®], MedReleaf[®], Pedanios[®], IndiMed[™], San Raf[®], Tasty's[®] and Whistler Medical Marijuana Co.[®]. The company also holds a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis[™].

Learn more at www.auroramj.com and follow us on [X](#) and [LinkedIn](#).

Aurora's common shares trade on the **NASDAQ** and **TSX** under the symbol "**ACB**".

Contact: Michelle Lefler | VP, Communications & PR | media@auroramj.com | For Investors: ICR, Inc. | aurora@icrinc.com